Latest Auditing News

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

Unith Ltd boosted its AI digital human platform with ISO/IEC 27001:2022 certification, launched new SDKs, and secured $2.75 million in fresh capital to fuel growth and commercial expansion.

Predictive Discovery reported a 33% increase in gold production to 64,026 ounces in Q2 2026, driven by Kiniero’s operational ramp-up and advancing development at the Bankan project.

Aurora Labs marked its commercial debut by delivering AU4 micro gas turbine propulsion systems to Sovereign Propulsion Systems, while securing a $1 million government grant to scale production and formalising a strategic defence partnership with MBDA.

Metallium has validated its Flash Joule Heating technology through extensive testing and multi-reactor operation, advancing towards commercial e-waste processing at its Texas campus in H1 2027.

Berkeley Energia has reported a maiden inferred lithium and rubidium resource at its Conchas Project in Spain, alongside appointing former Endesa CEO José Bogas Gálvez to its board, while continuing a US$1.25 billion arbitration against Spain over its Salamanca uranium project.

Lunnon Metals boosts cash to $22.2 million as Lady Herial mining wraps up, launching a record $13 million exploration budget targeting up to 2.4 million ounces of gold at Foster-Baker.

Tungsten Mining has locked in a robust economic case for its Watershed project with a pre-tax NPV of A$1.31 billion and IRR near 200%, while launching its largest-ever drilling campaign at Mt Mulgine to underpin long-term growth.

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.

Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.

Whitehaven Coal delivered a robust finish to FY26, hitting top-end guidance for production and sales while improving safety and reducing costs.